

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

1325 Selected Articles from This Issue

MCT FIRST DISCLOSURE

1327 **ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models**

Roger A. Smith, David J. Zammit, Nitin K. Damle, Helen Usansky, Sanjeeva P. Reddy, Jun-Hsiang Lin, Mahesh Mistry, Niranjana S. Rao, Louis J. Denis, and Sandeep Gupta

1338 **Harnessing the hERG1/ β 1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers**

Claudia Duranti, Jessica Iorio, Tiziano Lottini, Elena Lastraioli, Silvia Crescioli, Giacomo Bagni, Matteo Lulli, Chiara Capitani, Rayhana Bouazzi, Matteo Stefanini, Laura Carraresi, Luisa Iamele, Hugo De Jonge, and Annarosa Arcangeli

REVIEWS

1350 **Targeting Solid Tumors Using CD3 Bispecific Antibodies**

Alison Crawford and Danica Chiu

1359 **New Insights Into Platelet-enriched miRNAs: Production, Functions, Roles in Tumors, and Potential Targets for Tumor Diagnosis and Treatment**

Shuo Miao, Qingsong Zhang, Wenguang Chang, and Jianxun Wang

SMALL MOLECULE THERAPEUTICS

1367 **Evaluation of the Small-molecule BRD4 Degradator CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models**

Danlin Sun, Anna S. Nikonova, Peishan Zhang, Alexander Y. Deneka, Mark E. Fitzgerald, Ryan E. Michael, Linda Lee, Anna C. Lilly, Stewart L. Fisher, Andrew J. Phillips, Christopher G. Nasveschuk, David A. Proia, Zhigang Tu, and Erica A. Golemis

1378 **M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β 5i) Delivering Efficacy in Multiple Myeloma Models**

Michael P. Sanderson, Manja Friese-Hamim, Gina Walter-Bausch, Michael Busch, Stefanie Gaus, Djordje Musil, Felix Rohdich, Ugo Zanelli, Sondra L. Downey-Kopyscinski, Constantine S. Mitsiades, Oliver Schadt, Markus Klein, and Christina Esdar

1388 **CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment**

Tomohiro Fujiwara, Mohamed A. Yakoub, Andrew Chandler, Alexander B. Christ, Guangli Yang, Ouathek Ouerfelli, Vinagolu K. Rajasekhar, Aki Yoshida, Hiroya Kondo, Toshiaki Hata, Hiroshi Tazawa, Yildirim Dogan, Malcolm A.S. Moore, Toshiyoshi Fujiwara, Toshifumi Ozaki, Ed Purdue, and John H. Healey

1400 **Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma**

Krista M. Dalton, Kateryna Krytska, Timothy L. Lochmann, Renata Sano, Colleen Casey, Alessia D'Aulerio, Qasim A. Khan, Giovanna Stein Crowther, Colin Coon, Jinyang Cai, Sheeba Jacob, Richard Kurupi, Bin Hu, Mikhail Dozmorov, Patricia Greninger, Andrew J. Souers, Cyril H. Benes, Yael P. Mossé, and Anthony C. Faber

1412 **Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects**

Hiroshi Ureshino, Yuki Kurahashi, Tatsuro Watanabe, Satoshi Yamashita, Kazuharu Kamachi, Yuta Yamamoto, Yuki Fukuda-Kurahashi, Nao Yoshida-Sakai, Naoko Hattori, Yoshihiro Hayashi, Atsushi Kawaguchi, Kaoru Tohyama, Seiji Okada, Hironori Harada, Toshikazu Ushijima, and Shinya Kimura

TABLE OF CONTENTS

1422 Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways

Luigi Scotto, Cristina Kinahan, Eugene Douglass, Changchun Deng, Maryam Safari, Beatrice Casadei, Enrica Marchi, Jennifer K. Lue, Francesca Montanari, Lorenzo Falchi, Changhong Qiao, Nandakumar Renu, Susan E. Bates, Andrea Califano, and Owen A. O'Connor

1431 Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents

Ukhyun Jo, Ilya S. Senatorov, Astrid Zimmermann, Liton Kumar Saha, Yasuhisa Murai, Se Hyun Kim, Vinodh N. Rajapakse, Fathi Elloumi, Nobuyuki Takahashi, Christopher W. Schultz, Anish Thomas, Frank T. Zenke, and Yves Pommier

LARGE MOLECULE THERAPEUTICS

1442 First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

Mark D. Pegram, Erika P. Hamilton, Antoinette R. Tan, Anna Maria Storniolo, Kemal Balic, Anton I. Rosenbaum, Meina Liang, Peng He, Shannon Marshall, Anita Scheuber, Mayukh Das, and Manish R. Patel

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1454 Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent

Eddy S. Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, Deborah L. Della Manna, David A. Braun, Mahsa Zarei, Heng Du, Sumanta K. Pal, Gurudatta Naik, and Guru P. Sonpavde

MODELS AND TECHNOLOGIES

1462 International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer

Gilles Vassal, Peter J. Houghton, Stefan M. Pfister, Malcolm A. Smith, Huib N. Caron, Xiao-Nan Li, David J. Shields, Olaf Witt, Jan J. Molenaar, Sara Colombetti, Julia Schüler, and Lou F. Stancato

1469 Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling

Deborah R. Surman, Yuan Xu, Min-Jung Lee, Jane Trepel, Kate Brown, Maheshwari Ramineni, Taylor G. Splawn, Laurence P. Diggs, H. Courtney Hodges, Jeremy L. Davis, Hyun-Sung Lee, Bryan M. Burt, and Robert Taylor Ripley

1481 Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing

Tomoyoshi Inoue, Thomas Byrne, Mitsuko Inoue, Madeline E. Tait, Patrick Wall, Annabel Wang, Michael R. Dermeyer, Hanane Laklai, Joseph J. Binder, Clare Lees, Robert Hollingsworth, Liliana Maruri-Avidal, David H. Kirn, and Donald M. McDonald

CORRECTION


1495 Correction: SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ

Monica Brenca, Sabrina Rossi, Erica Lorenzetto, Elena Piccinin, Sara Piccinin, Francesca Maria Rossi, Alberto Giuliano, Angelo Paolo Dei Tos, Roberta Maestro, and Piergiorgio Modena

TABLE OF CONTENTS

ABOUT THE COVER

The hERG1 potassium channel is found on pathological tissue, such as many cancers, as well as non-pathological tissue such as the heart. By generating a bispecific antibody in the form of a single-chain diabody (scDb) to both the hERG1 channel and the $\beta 1$ subunit of integrin receptors, Duranti and colleagues have created a potent therapeutic with good pharmacokinetics and no observed cardiac or renal toxicity. Read the full article on page 1338.



Molecular Cancer Therapeutics

20 (8)

Mol Cancer Ther 2021;20:1325-1495.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/20/8>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/8>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.